The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo

Cancer Letters

Volumn 325, Issue 2, 2012, Pages 139-146

  Ren, Hui ^a,b   Chen, Mingwei ^a   Yue, Ping ^b   Tao, Hui ^b   Owonikoko, Taofeek K ^b   Ramalingam, Suresh S ^b   Khuri, Fadlo R ^b   Sun, Shi Yong ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BKM120; Lung cancer; MTOR; PI3 kinase; RAD001

Indexed keywords

BUPARLISIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P21; PROTEIN P53; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84865633677     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.06.018     Document Type: Review

References (27)

1. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
2. Chen Y.L., Law P.Y., Loh H.H. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr. Med. Chem. Anti-Cancer Agents 2005, 5:575-589.
3. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008, 11:32-50.
4. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13:433-442.
5. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., Schnell C., Guthy D., Nagel T., Wiesmann M., Brachmann S., Fritsch C., Dorsch M., Chene P., Shoemaker K., De Pover A., Menezes D., Martiny-Baron G., Fabbro D., Wilson C.J., Schlegel R., Hofmann F., Garcia-Echeverria C., Sellers W.R., Voliva C.F. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 2012, 11:317-328.
6. Zheng Y., Yang J., Qian J., Zhang L., Lu Y., Li H., Lin H., Lan Y., Liu Z., He J., Hong S., Thomas S., Shah J., Baladandayuthapani V., Kwak L.W., Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J. Mol. Med. (Berl) 2011.
7. Koul D., Fu J., Shen R., LaFortune T.A., Wang S., Tiao N., Kim Y.W., Liu J.L., Ramnarian D., Yuan Y., Garcia-Echevrria C., Maira S.M., Yung W.K. Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 2012, 18:184-195.
8. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., Demanse D., De Buck S.S., Ru Q.C., Peters M., Goldbrunner M., Baselga J. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30:282-290.
9. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
10. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl. J. Med. 2011, 364:514-523.
11. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 2007, 13:3109-3114.
12. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008, 68:7409-7418.
13. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
14. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
15. Wang X., Sun S.Y. Enhancing mTOR-targeted cancer therapy. Exp. Opin. Ther. Targets 2009, 13:1193-1203.
16. Sun S.Y., Yue P., Dawson M.I., Shroot B., Michel S., Lamph W.W., Heyman R.A., Teng M., Chandraratna R.A., Shudo K., Hong W.K., Lotan R. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 1997, 57:4931-4939.
17. Elrod H.A., Lin Y.D., Yue P., Wang X., Lonial S., Khuri F.R., Sun S.Y. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol. Cancer Ther. 2007, 6:2029-2038.
18. Wang X., Hawk N., Yue P., Kauh J., Ramalingam S.S., Fu H., Khuri F.R., Sun S.Y. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther. 2008, 7:1952-1958.
19. Sun S.Y., Yue P., Shroot B., Hong W.K., Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J. Cell Physiol. 1997, 173:279-284.
20. Sun S.Y., Zhou Z., Wang R., Fu H., Khuri F.R. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biol. Ther. 2004, 3:1092-1098.
21. Liu X., Yue P., Zhou Z., Khuri F.R., Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 2004, 96:1769-1780.
22. Sun S.Y., Yue P., Wu G.S., El-Deiry W.S., Shroot B., Hong W.K., Lotan R. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999, 18:2357-2365.
23. Wang X., Yue P., Chan C.B., Ye K., Ueda T., Watanabe-Fukunaga R., Fukunaga R., Fu H., Khuri F.R., Sun S.Y. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation. Mol. Cell Biol. 2007.
24. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12:175-180.
25. Sanders H.R., Albitar M. Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genet. Cytogenet. 2010, 203:7-15.
26. Wang X., Yue P., Chan C.B., Ye K., Ueda T., Watanabe-Fukunaga R., Fukunaga R., Fu H., Khuri F.R., Sun S.Y. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell Biol. 2007, 27:7405-7413.
27. Abbas T., Dutta A. P21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.